BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26383032)

  • 1. Acquisition of conditioned fear is followed by region-specific changes in RNA editing of glutamate receptors.
    Brande-Eilat N; Golumbic YN; Zaidan H; Gaisler-Salomon I
    Stress; 2015; 18(3):309-18. PubMed ID: 26383032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and activity in primary cortical neurons.
    Bonini D; Filippini A; La Via L; Fiorentini C; Fumagalli F; Colombi M; Barbon A
    RNA Biol; 2015; 12(1):43-53. PubMed ID: 25625181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients.
    Yamashita T; Kwak S
    Brain Res; 2014 Oct; 1584():28-38. PubMed ID: 24355598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine Deaminase That Acts on RNA 3 (ADAR3) Binding to Glutamate Receptor Subunit B Pre-mRNA Inhibits RNA Editing in Glioblastoma.
    Oakes E; Anderson A; Cohen-Gadol A; Hundley HA
    J Biol Chem; 2017 Mar; 292(10):4326-4335. PubMed ID: 28167531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA editing of the Q/R site of GluA2 in different cultured cell lines that constitutively express different levels of RNA editing enzyme ADAR2.
    Yamashita T; Tadami C; Nishimoto Y; Hideyama T; Kimura D; Suzuki T; Kwak S
    Neurosci Res; 2012 May; 73(1):42-8. PubMed ID: 22366356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons.
    Hideyama T; Yamashita T; Aizawa H; Tsuji S; Kakita A; Takahashi H; Kwak S
    Neurobiol Dis; 2012 Mar; 45(3):1121-8. PubMed ID: 22226999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAR2-dependent GluA2 editing regulates cocaine seeking.
    Schmidt HD; McFarland KN; Darnell SB; Huizenga MN; Sangrey GR; Cha JH; Pierce RC; Sadri-Vakili G
    Mol Psychiatry; 2015 Nov; 20(11):1460-6. PubMed ID: 25349168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new mouse line with reduced GluA2 Q/R site RNA editing exhibits loss of dendritic spines, hippocampal CA1-neuron loss, learning and memory impairments and NMDA receptor-independent seizure vulnerability.
    Konen LM; Wright AL; Royle GA; Morris GP; Lau BK; Seow PW; Zinn R; Milham LT; Vaughan CW; Vissel B
    Mol Brain; 2020 Feb; 13(1):27. PubMed ID: 32102661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low editing efficiency of GluR2 mRNA is associated with a low relative abundance of ADAR2 mRNA in white matter of normal human brain.
    Kawahara Y; Ito K; Sun H; Kanazawa I; Kwak S
    Eur J Neurosci; 2003 Jul; 18(1):23-33. PubMed ID: 12859334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease.
    Gaisler-Salomon I; Kravitz E; Feiler Y; Safran M; Biegon A; Amariglio N; Rechavi G
    Neurobiol Aging; 2014 Aug; 35(8):1785-91. PubMed ID: 24679603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic increase of the RNA editing for glutamate receptor subunits during terminal differentiation of clonal human neurons.
    Lai F; Chen CX; Lee VM; Nishikura K
    J Neurochem; 1997 Jul; 69(1):43-52. PubMed ID: 9202292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new strategy to increase RNA editing at the Q/R site of GluA2 AMPA receptor subunits by targeting alternative splicing patterns of ADAR2.
    Chaytow H; Sethw Hassan I; Akbar S; Popplewell L; Dickson G; Chen PE
    J Neurosci Methods; 2021 Dec; 364():109357. PubMed ID: 34536489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAR2-mediated Q/R editing of GluK2 regulates kainate receptor upscaling in response to suppression of synaptic activity.
    Gurung S; Evans AJ; Wilkinson KA; Henley JM
    J Cell Sci; 2018 Dec; 131(24):. PubMed ID: 30559217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA editing enzyme ADAR2 is a mediator of neuropathic pain after peripheral nerve injury.
    Uchida H; Matsumura S; Okada S; Suzuki T; Minami T; Ito S
    FASEB J; 2017 May; 31(5):1847-1855. PubMed ID: 28126736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons.
    Whitney NP; Peng H; Erdmann NB; Tian C; Monaghan DT; Zheng JC
    FASEB J; 2008 Aug; 22(8):2888-900. PubMed ID: 18403631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editing status at the Q/R site of the GluR2 and GluR6 glutamate receptor subunits in the surgically excised hippocampus of patients with refractory epilepsy.
    Grigorenko EV; Bell WL; Glazier S; Pons T; Deadwyler S
    Neuroreport; 1998 Jul; 9(10):2219-24. PubMed ID: 9694203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia.
    Kubota-Sakashita M; Iwamoto K; Bundo M; Kato T
    Mol Brain; 2014 Jan; 7():5. PubMed ID: 24443933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enduring abolishment of remote but not recent expression of conditioned fear by the blockade of calcium-permeable AMPA receptors before extinction training.
    Zelena D; Mikics É; Balázsfi D; Varga J; Klausz B; Urbán E; Sipos E; Biró L; Miskolczi C; Kovács K; Ferenczi S; Haller J
    Psychopharmacology (Berl); 2016 Jun; 233(11):2065-2076. PubMed ID: 27020785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2.
    Higuchi M; Maas S; Single FN; Hartner J; Rozov A; Burnashev N; Feldmeyer D; Sprengel R; Seeburg PH
    Nature; 2000 Jul; 406(6791):78-81. PubMed ID: 10894545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone impedes glutamate excitotoxicity in a valproic acid rat model of autism: Role of ADAR2 in AMPA GluA2 RNA editing.
    Habib MZ; Elnahas EM; Aboul-Ela YM; Ebeid MA; Tarek M; Sadek DR; Negm EA; Abdelhakam DA; Aboul-Fotouh S
    Eur J Pharmacol; 2023 Sep; 955():175916. PubMed ID: 37460052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.